A roadmap for driving CAR T cells toward the oncogenic immunopeptidome

Melita Irving; Vincent Zoete; Michal Bassani-Sternberg; George Coukos

doi:10.1016/j.ccell.2021.12.011

A roadmap for driving CAR T cells toward the oncogenic immunopeptidome

Cancer Cell. 2022 Jan 10;40(1):20-22. doi: 10.1016/j.ccell.2021.12.011.

Authors

Melita Irving¹, Vincent Zoete², Michal Bassani-Sternberg³, George Coukos³

Affiliations

¹ Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne Teaching Hospital and University of Lausanne, Lausanne, Switzerland. Electronic address: melita.irving@unil.ch.
² Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne Teaching Hospital and University of Lausanne, Lausanne, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
³ Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne Teaching Hospital and University of Lausanne, Lausanne, Switzerland.

PMID: 35016027
DOI: 10.1016/j.ccell.2021.12.011

Abstract

A critical barrier to CAR T cell therapy is the paucity of target antigens that are broadly and stably expressed exclusively in tumors. In their comprehensive multi-omics and pre-clinical study, Yarmarkovich et al. provide proof of principle for the development and efficacy of peptide centric (PC)-CARs targeting the oncogenic immunopeptidome of neuroblastoma.

Publication types

Comment

MeSH terms

Carcinogenesis
Humans
Immunotherapy, Adoptive*
Neuroblastoma*
T-Lymphocytes